Obetix 40 mg (Obeticholic Acid) Tablets

Introduction:

Obetix 40 mg, manufactured by Beacon Pharmaceuticals Ltd and supplied by Orio Pharma, is an advanced medication used in the treatment of primary biliary cholangitis (PBC). Containing Obeticholic Acid, Obetix 40 mg works by activating the farnesoid X receptor (FXR), which plays a key role in regulating bile acid production and inflammation in the liver. This targeted therapy is designed to slow the progression of PBC, improve liver function, and ultimately enhance the quality of life for patients with this chronic liver disease.

Manufacturing Excellence of Beacon Pharmaceuticals Ltd.:

Beacon Pharmaceuticals Ltd. is dedicated to producing high-quality pharmaceutical products that adhere to stringent international standards. The development of Obetix 40 mg reflects Beacon’s commitment to advancing liver disease treatments through innovative research, rigorous quality control, and adherence to best manufacturing practices. Their focus on safety and efficacy ensures that Obetix 40 mg is a reliable and effective option for patients managing primary biliary cholangitis.

Mechanism of Action:

Obetix 40 mg contains Obeticholic Acid, a potent FXR agonist that targets the nuclear receptor involved in bile acid metabolism. By activating FXR, Obeticholic Acid reduces the production of bile acids and decreases their accumulation in the liver, which is a hallmark of PBC. Additionally, FXR activation helps to reduce liver inflammation and fibrosis, further protecting the liver from damage. This dual action makes Obetix 40 mg an effective treatment for PBC, helping to slow disease progression and improve overall liver function.

Clinical Applications:

Obetix 40 mg is indicated for the treatment of:

• Primary Biliary Cholangitis (PBC): Obetix 40 mg is used in adult patients with PBC, particularly those who have not responded adequately to or are intolerant of ursodeoxycholic acid (UDCA), the standard treatment for this condition.

Clinical studies have demonstrated that Obeticholic Acid significantly improves liver function tests, including alkaline phosphatase (ALP) and bilirubin levels, in patients with PBC, making it a valuable option for those with this challenging liver disease.

Dosage and Administration:

The recommended starting dosage of Obetix 40 mg for PBC patients is 5 mg once daily, with the potential to increase to 10 mg daily based on patient tolerance and response to treatment. The tablet should be taken orally with or without food. It is crucial for patients to follow their healthcare provider’s instructions carefully and to undergo regular monitoring of liver function to assess the effectiveness of the therapy and adjust the dosage as necessary. Patients should also be monitored for signs of liver-related side effects, including worsening liver function or symptoms of decompensation.

Benefits of Obetix 40 mg:

• Targeted Therapy for PBC: Obetix 40 mg offers a targeted approach to treating PBC by modulating bile acid production and reducing liver inflammation and fibrosis.
• Improved Liver Function: Clinical evidence shows that Obetix 40 mg significantly improves key liver function markers, slowing disease progression and reducing the risk of liver-related complications.
• Alternative for UDCA Non-Responders: Obetix 40 mg provides an effective treatment option for patients who do not respond adequately to or cannot tolerate UDCA.
• Convenient Oral Administration: The once-daily dosing of Obetix 40 mg offers convenience and supports adherence to the treatment regimen, enhancing patient outcomes.

Supplier: Orio Pharma

Orio Pharma ensures that Obetix 40 mg is readily available to healthcare providers and patients, offering reliable access to this essential therapy for primary biliary cholangitis. Their commitment to efficient supply and distribution supports effective management of PBC, helping to improve patient outcomes.

Conclusion:

Obetix 40 mg (Obeticholic Acid) by Beacon Pharmaceuticals Ltd, supplied by Orio Pharma, represents a significant advancement in the treatment of primary biliary cholangitis. This targeted therapy offers a crucial option for patients with PBC, particularly those who are not adequately managed with standard therapy. By incorporating Obetix 40 mg into their treatment plans, healthcare providers can offer patients a reliable and effective strategy for improving liver function, slowing disease progression, and enhancing quality of life.